Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.

Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M.

Leukemia. 1992 Aug;6(8):754-60.

PMID:
1640725
2.

Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.

Lion T, Gaiger A, Henn T, Hörth E, Haas OA, Geissler K, Gadner H.

Leukemia. 1995 Aug;9(8):1353-60.

PMID:
7643624
4.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Sep;17(9):1687-94.

PMID:
12970765
5.

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2002 Sep;16(9):1579-83.

6.

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.

Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.

Blood. 1996 Feb 15;87(4):1549-55.

9.

Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay.

Preudhomme C, Chams-Eddine L, Roumier C, Duflos-Grardel N, Denis C, Cosson A, Fenaux P.

Leukemia. 1999 May;13(5):818-23.

PMID:
10374889
10.

Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation.

Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass S.

Br J Haematol. 1992 Dec;82(4):708-14.

PMID:
1482658
11.

Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy.

Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, Tanzer J, Grandchamp B.

Br J Haematol. 1992 Dec;82(4):701-7.

PMID:
1482657
12.

Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.

Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.

Br J Haematol. 1995 Sep;91(1):126-31.

PMID:
7577619
13.

Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.

Okamoto R, Harano H, Matsuzaki M, Motomura S, Maruta A, Kodama F, Mohri H, Okubo T.

Am J Clin Pathol. 1995 Nov;104(5):510-6.

PMID:
7572810
14.
15.

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Dec;17(12):2392-400.

PMID:
14523462
16.
19.

Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.

Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA.

Blood. 1992 Apr 15;79(8):1920-3.

20.

Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.

Wandl UB, Bützler R, Niederle N, Kloke O, Mengelkoch B, Becher R, Seeber S, Opalka B.

Leukemia. 1994 May;8(5):776-9.

PMID:
7514245

Supplemental Content

Support Center